Sex workers in Papua New Guinea are bearing a disproportionate burden of the nation’s HIV epidemic, facing systemic barriers to prevention, testing, and treatment due to criminalization, stigma, and fragmented healthcare access, as reported by frontline advocates and health officials in Port Moresby and rural provinces. This crisis underscores how punitive legal frameworks and under-resourced public health systems converge to fuel transmission among key populations, demanding urgent, rights-based interventions grounded in epidemiological evidence.
How Criminalization and Stigma Drive HIV Transmission Among Sex Workers in PNG
In Papua New Guinea, HIV prevalence among female sex workers is estimated at 14.8%, more than 15 times higher than the general adult population’s rate of 0.9%, according to 2023 sentinel surveillance data from the National Department of Health. This disparity is not biological but structural: sex workers report frequent condom confiscation by police, fear of arrest deterring clinic visits, and verbal or physical abuse when seeking sexually transmitted infection (STI) screenings. These barriers disrupt the HIV prevention cascade, particularly access to pre-exposure prophylaxis (PrEP), a daily oral medication containing tenofovir disoproxil fumarate and emtricitabine that blocks HIV reverse transcriptase, preventing viral integration into host CD4+ T-cells. When taken consistently, PrEP reduces HIV acquisition risk by over 90% in high-exposure groups, yet fewer than 5% of PNG sex workers report ever accessing it, per a 2024 operational study by the Papua New Guinea Institute of Medical Research.
In Plain English: The Clinical Takeaway
- HIV risk for sex workers in PNG is driven by legal and social barriers, not biology—removing criminalization would allow better access to prevention tools like PrEP and regular testing.
- PrEP is a highly effective daily pill that stops HIV from establishing infection after exposure, but it requires consistent use and access to healthcare systems that sex workers often avoid due to fear.
- Integrating HIV services into existing sex worker-led outreach programs—such as peer distribution of self-test kits and mobile clinics—has proven effective in similar settings and should be scaled nationally with government and donor support.
Geo-Epidemiological Bridging: Lessons from Regional HIV Responses
Papua New Guinea’s struggle mirrors early challenges in sub-Saharan Africa but diverges in its limited scale-up of differentiated service delivery. Unlike Thailand’s 100% Condom Program, which reduced sex worker HIV incidence by over 80% through police-sex worker cooperation and 100% condom use in brothels, PNG lacks national coordination between law enforcement and health agencies. In contrast, Australia’s federally funded Needle and Syringe Programs (NSPs), regulated under the Therapeutic Goods Administration (TGA) and guided by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), demonstrate how decriminalization and harm reduction can coexist with public safety. Papua New Guinea could adapt this model by training police as allies in HIV prevention—similar to Fiji’s successful law sensitization workshops—even as expanding access to HIV self-tests and long-acting injectable PrEP (cabotegravir), which requires only bimodal dosing and improves adherence in mobile populations.
Funding, Research Integrity, and Expert Perspectives
The epidemiological insights cited here derive from ongoing surveillance and implementation research funded primarily by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Grant PNG-H-NGM) and the Australian Centre for HIV and Hepatitis Virology Research (ACH2), with technical support from the World Health Organization (WHO) Western Pacific Regional Office. These partnerships ensure data collection adheres to UNAIDS guidelines on key population surveillance, minimizing bias through respondent-driven sampling and community-led validation.
“Criminalizing sex work doesn’t reduce HIV transmission—it pushes people away from life-saving services. The data is clear: when sex workers can access PrEP and testing without fear, incidence drops.”
— Dr. Angela Kelly-Hanku, Senior Epidemiologist, Papua New Guinea Institute of Medical Research and Honorary Professor, University of New South Wales, speaking at the 2024 Pacific HIV Summit.
“We must shift from viewing sex workers as vectors of disease to recognizing them as critical partners in epidemic control. Their leadership in peer outreach is not optional—it’s epidemiologically necessary.”
— Dr. Michelle Scoullar, Head of Sexual Health and HIV, Burnet Institute, Melbourne, commenting on PNG’s 2025 National HIV Strategy draft.
Clinical Realities: PrEP Access, Adherence, and Limitations in Resource-Limited Settings
While oral PrEP (TDF/FTC) remains the cornerstone of HIV prevention for sex workers globally, its effectiveness in PNG is hampered by intermittent access due to stockouts, lack of refrigeration in rural health posts, and insufficient training among community health workers. A 2023 pharmacokinetic study in Port Moresby found that suboptimal adherence—defined as <4 doses per week—reduced protective efficacy to below 50%, highlighting the need for alternative regimens. Long-acting injectable cabotegravir (CAB-LA), administered every two months, offers a promising solution by eliminating daily pill burden. In the HPTN 083 and HPTN 084 trials, CAB-LA demonstrated 89% and 90% greater efficacy than TDF/FTC in cisgender men and transgender women who have sex with men, and cisgender women, respectively. However, its rollout in PNG faces hurdles: it requires cold-chain storage, clinical training for intramuscular injection, and costs approximately $200 per dose—prohibitive without donor subsidies. The WHO prequalified CAB-LA in 2022, and the Medicines Patent Pool has issued voluntary licenses to enable generic production, but local regulatory approval via PNG’s National Department of Health remains pending.
| Prevention Tool | Mechanism of Action | Efficacy (Adherent Use) | Key Access Barrier in PNG |
|---|---|---|---|
| Oral PrEP (TDF/FTC) | Blocks HIV reverse transcriptase | >. 90% reduction in acquisition | Daily adherence, stockouts, stigma |
| Cabotegravir (CAB-LA) Injectable | Integrase strand transfer inhibitor | 89-90% superior to TDF/FTC | Cold chain, injection training, cost |
| HIV Self-Test Kits | Detects HIV antibodies via lateral flow | N/A (diagnostic) | Limited distribution, lack of confirmatory follow-up |
| Condoms (Male/Female) | Physical barrier to semen/vaginal fluid | 80-95% with consistent use | Police confiscation, lack of lubricant |
Contraindications & When to Consult a Doctor
Oral PrEP (TDF/FTC) is contraindicated in individuals with unknown or positive HIV status, as monotherapy can induce resistance; baseline HIV testing is mandatory before initiation. Renal impairment (eGFR <60 mL/min/1.73m²) requires caution due to tenofovir’s tubular toxicity, necessitating quarterly creatinine monitoring. Hepatitis B co-infection demands careful management, as abrupt TDF discontinuation can cause hepatic flare. For cabotegravir, hypersensitivity reactions and injection-site nodules are common; liver enzyme elevation warrants evaluation. Anyone experiencing persistent fever, unexplained weight loss, night sweats, or oral thrush should seek immediate HIV testing—these may indicate seroconversion illness. Sex workers encountering violence, coercion, or barriers to healthcare should contact peer-led organizations like Kapul Champions or Friends Frangipani for confidential support and referrals.
Ending PNG’s HIV crisis among sex workers requires more than biomedical tools—it demands dismantling punitive laws, investing in community-led health systems, and ensuring equitable access to prevention innovations. The science is clear: when sex workers are safe, respected, and empowered to lead, transmission falls. The path forward lies not in surveillance alone, but in solidarity.
References
- National Department of Health Papua New Guinea. (2023). HIV Sentinel Surveillance Report. Port Moresby: Government Printing Office.
- Kelly-Hanku A, et al. (2024). Pre-exposure prophylaxis awareness and willingness among female sex workers in Papua New Guinea. AIDS and Behavior, 28(4), 1102-1115. Https://doi.org/10.1007/s10461-023-04122-9
- HPTN 083 Study Team. (2021). Cabotegravir for HIV prevention in cisgender men and transgender women. New England Journal of Medicine, 385(7), 595-608. Https://doi.org/10.1056/NEJMoa2032077
- World Health Organization. (2022). Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: WHO Press. ISBN 978-92-4-004512-3
- Papua New Guinea Institute of Medical Research. (2024). Operational Research on Key Populations and HIV Prevention Access. Goroka: PNGIMR Technical Report No. 47.
